Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064347 | 0.81 | KDM4C (0.51) | ALDH1A1MAPTHTR2AKDM4EHTR2C | |
| SCHEMBL18085715 | 0.81 | HTR2A (0.60) | ALDH1A1MAPTHTR2AHTR2CKMT2A | |
| SCHEMBL13144356 | 0.78 | MAPT (0.50) | ALDH1A1MAPTKDM4ECOMTPOLB | |
| SCHEMBL323525 | 0.76 | MAPT (0.49) | ALDH1A1MAPTPKMKDM4ECOMT | |
| SCHEMBL1095146 | 0.76 | ALDH1A1 (0.49) | ALDH1A1MAPTHTR2AHTR2CCOMT | |
| SCHEMBL2064569 | 0.76 | MAPT (0.49) | ALDH1A1MAPTHTR2AKDM4EHTR2C | |
| SCHEMBL364560 | 0.76 | MAPT (0.65) | ALDH1A1MAPTHTR2AHTR2CCOMT | |
| SCHEMBL19442040 | 0.76 | ALDH1A1 (0.46) | ALDH1A1MAPTHTR2AKDM4EHTR2C | |
| SCHEMBL15095491 | 0.74 | ALDH1A1 (0.50) | ALDH1A1MAPTHTR2AHTR2CCOMT | |
| SCHEMBL16705330 | 0.74 | MAPT (0.47) | ALDH1A1MAPTKDM4ECOMTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186748-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATERS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186748-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATERS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-20180186748-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATERS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9783502-B2 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783502-B2 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783502-B2 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160272591-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160272591-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20160272591-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-9199940-B2 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130296321-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8481535-B2 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481535-B2 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481535-B2 | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor | ARENA PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100234380-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234380-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234380-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| EP-2018372-A2 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | Arena Pharmaceuticals, Inc. (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007136689-A2 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136689-A2 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296321-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR2A, HTR5A, HTR2C | ALDH1A1 2088/4885MAPT 1044/4885PKM 765/4885 |
| US-20180186748-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATERS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR2A, HTR5A, HTR2C | ALDH1A1 2271/4885MAPT 1019/4885PKM 791/4885 |
| US-20100234380-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR2A, HTR5A, HTR2C | ALDH1A1 2088/4885MAPT 1044/4885PKM 765/4885 |
| US-20160272591-A1 | CRYSTALLINE FORMS AND PROCESSES FOR THE PREPARATION OF PHENYL-PYRAZOLES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR | HTR2A, HTR5A, HTR2C | ALDH1A1 2088/4885MAPT 1044/4885PKM 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.